Kopran Limited

NSE KOPRAN.NS

Kopran Limited Current Liabilities for the year ending March 31, 2024: USD 26.20 M

Kopran Limited Current Liabilities is USD 26.20 M for the year ending March 31, 2024, a 21.68% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Kopran Limited Current Liabilities for the year ending March 31, 2023 was USD 21.53 M, a 7.86% change year over year.
Kopran Limited Current Liabilities for the year ending March 31, 2022 was USD 19.96 M, a -9.03% change year over year.
Kopran Limited Current Liabilities for the year ending March 31, 2021 was USD 21.94 M, a 18.08% change year over year.
Kopran Limited Current Liabilities for the year ending March 31, 2020 was USD 18.59 M, a -4.13% change year over year.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

NSE: KOPRAN.NS

Kopran Limited

CEO	Mr. Surendra Shrikrishna Somani B.Com.
IPO Date	July 1, 2002
Location	India
Headquarters	Parijat House
Employees	842
Sector	Healthcare
Industries Pharmaceuticals Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care Plastics

Description

Kopran Limited, an integrated pharmaceutical company, manufactures and sells active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, dry powder, suspension, and injectables. It also provides active pharmaceutical ingredients in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti-helmentics, anti-histamine, anti-acne, anti-infective, urological, anti-thrombotic, antidiabetic, pain management, gastroenterology, and cardiovascular. The company was incorporated in 1958 and is headquartered in Mumbai, India.

Key trends

Past 5 years